
OpGen OPGN
Quarterly report 2025-Q3
added 11-19-2025
OpGen P/CF Ratio 2011-2026 | OPGN
Annual P/CF Ratio OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.87 | -0.14 | -0.0183 | -0.0751 | -1.46 | -0.213 | -0.803 | -0.54 | -1.2 | -0.784 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.0183 | -1.87 | -0.71 |
P/CF Ratio of other stocks in the Diagnostics research industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
26.1 | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
28.3 | $ 113.56 | -1.11 % | $ 34.5 B | ||
|
CareDx, Inc
CDNA
|
23.6 | $ 17.43 | -2.19 % | $ 929 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-47.7 | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.15 | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
-40.2 | $ 16.35 | 0.28 % | $ 176 M | ||
|
Co-Diagnostics
CODX
|
-0.201 | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
NeoGenomics
NEO
|
284 | $ 7.94 | -1.0 % | $ 1.02 B | ||
|
Aspira Women's Health
AWH
|
-1.41 | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.826 | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
0.396 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-17.1 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-1.63 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.94 | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
10.4 | $ 166.63 | -0.95 % | $ 8.26 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
21.8 | - | - | $ 10.7 B | ||
|
Danaher Corporation
DHR
|
23.3 | $ 189.61 | -1.29 % | $ 135 B | ||
|
Castle Biosciences
CSTL
|
10.9 | $ 25.04 | 1.25 % | $ 696 M | ||
|
Biocept
BIOC
|
-0.447 | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
-1.89 | $ 14.62 | -4.82 % | $ 1.9 B | ||
|
DexCom
DXCM
|
17.7 | $ 63.13 | -0.09 % | $ 24.6 B | ||
|
Fulgent Genetics
FLGT
|
22.2 | $ 16.16 | -1.58 % | $ 489 M | ||
|
Guardant Health
GH
|
-72.7 | $ 90.23 | 0.63 % | $ 11.3 B | ||
|
QIAGEN N.V.
QGEN
|
12.6 | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
-0.0144 | $ 2.58 | -0.39 % | $ 83.7 K | ||
|
Biomerica
BMRA
|
-1.87 | $ 2.13 | -1.61 % | $ 4.89 M | ||
|
ICON Public Limited Company
ICLR
|
12.9 | $ 108.25 | -1.25 % | $ 8.93 B | ||
|
Illumina
ILMN
|
19.6 | $ 126.36 | -1.08 % | $ 20.1 B | ||
|
BioNano Genomics
BNGO
|
-0.486 | $ 1.14 | -0.54 % | $ 6.21 M | ||
|
Interpace Biosciences
IDXG
|
1.26 | $ 1.98 | 0.51 % | $ 8.76 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.541 | - | - | $ 9.42 M | ||
|
Laboratory Corporation of America Holdings
LH
|
14.6 | $ 274.19 | -0.1 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
13.1 | $ 75.95 | 0.08 % | $ 5.13 B | ||
|
Celcuity
CELC
|
-35 | $ 115.01 | 0.69 % | $ 5.38 B | ||
|
Medpace Holdings
MEDP
|
18.2 | $ 495.15 | -0.17 % | $ 14.3 B | ||
|
DermTech
DMTK
|
-0.551 | - | -11.32 % | $ 2.94 M | ||
|
Chembio Diagnostics
CEMI
|
-0.991 | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
-0.00219 | - | -8.98 % | $ 14.8 K | ||
|
Myriad Genetics
MYGN
|
227 | $ 4.61 | -1.39 % | $ 427 M | ||
|
Exact Sciences Corporation
EXAS
|
39.7 | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
12.4 | $ 200.49 | 0.72 % | $ 22.3 B | ||
|
Neogen Corporation
NEOG
|
17.5 | $ 9.97 | 4.24 % | $ 2.16 B | ||
|
National Research Corporation
NRC
|
11.9 | $ 17.15 | -1.04 % | $ 384 M | ||
|
Natera
NTRA
|
-12.3 | $ 206.41 | 0.75 % | $ 20.3 B | ||
|
ENDRA Life Sciences
NDRA
|
-0.706 | $ 4.6 | -2.95 % | $ 3.62 M | ||
|
Pacific Biosciences of California
PACB
|
-4.48 | $ 1.39 | -2.46 % | $ 417 M | ||
|
Koninklijke Philips N.V.
PHG
|
26.5 | $ 26.96 | -0.92 % | $ 20 B | ||
|
Precipio
PRPO
|
56 | $ 26.0 | 0.08 % | $ 41.7 M | ||
|
Personalis
PSNL
|
-5.62 | $ 6.11 | -7.14 % | $ 362 M | ||
|
Heska Corporation
HSKA
|
-38.7 | - | - | $ 1.31 B |